Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and ...

Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. You’re listening to our weekly science news roundup. Let’s start off with a vaccine 180.

There’s something almost magical about clutching a crisp $20 bill while standing at the threshold of a place where that humble Andrew Jackson can transform into a treasure trove of possibilities.

Health Secretary Robert F. Kennedy Jr. has spent years campaigning against vaccines, but with the flu shot, he’s suggested it’s personal. Kennedy has linked his strained, raspy speech to the vaccine, ...

The Food and Drug Administration's decision, made public on Feb. 10, 2026, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from ...

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...

The Food and Drug Administration rattled the biotech industry last week when it said it wouldn't even look at Moderna's application to market the first mRNA flu shot. But on Wednesday, the agency ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA's decision this week to reverse course and review Moderna's seasonal flu vaccine application followed a meeting in which ...

WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna's new flu vaccine after all, resolving a dispute that had blocked the company's application for the first-of ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA flu vaccine candidate after holding a high-priority meeting with the company.

The FDA has made a U-turn on Moderna's experimental flu shot. After refusing to even review the vaccine last week over concerns about how the pivotal trial was designed, the agency has now agreed to ...